SSTR2 and neuroendocrine neoplasm: While this approach has not been translated yet for patient use, targeted radionuclide therapy has been established in clinics using somatostatin analogues such as [177Lu]Lu-DOTATATE (LutatheraTM) for targeting somatostatin receptor-2 (SSTR2)-positive neuroendocrine neoplasms [20].